Clinical Trial Update: A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study of TORL-5-700 is evaluating its safety and early efficacy in relapsed or refractory B-cell non-Hodgkin lymphoma; the trial is not yet recruiti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma

Drugs mentioned

• TORL-5-700

Snippet

Sponsor: TORL Biotherapeutics, LLC | Conditions: Histologically Confirmed Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING